Comparing NovoCure (NASDAQ:NVCR) and Heart Test Laboratories (NASDAQ:HSCSW)

NovoCure (NASDAQ:NVCR) and Heart Test Laboratories (NASDAQ:HSCSW) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Valuation and Earnings

This table compares NovoCure and Heart Test Laboratories”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35 million	3.04	-$136.23 million	($1.30)	-13.15
Heart Test Laboratories	$4,319.00	N/A	N/A	N/A	N/A

Heart Test Laboratories has lower revenue, but higher earnings than NovoCure.

Analyst Recommendations

This is a summary of current ratings and recommmendations for NovoCure and Heart Test Laboratories, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1	4	2	0	2.14
Heart Test Laboratories	0	0	0	0	0.00

NovoCure presently has a consensus target price of $21.20, suggesting a potential upside of 23.98%. Given NovoCure’s stronger consensus rating and higher possible upside, equities research analysts clearly believe NovoCure is more favorable than Heart Test Laboratories.

Insider and Institutional Ownership

84.6% of NovoCure shares are owned by institutional investors. 6.6% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares NovoCure and Heart Test Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Heart Test Laboratories	N/A	N/A	N/A

Summary

NovoCure beats Heart Test Laboratories on 6 of the 9 factors compared between the two stocks.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

About Heart Test Laboratories

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.